Body mass index, prognosis and mode of death in chronic heart failure: Results from the Valsartan Heart Failure Trial

Mariantonietta Cicoira, Aldo Pietro Maggioni, Roberto Latini, Simona Barlera, Elisa Carretta, Andras Janosi, Jordi Soler Soler, Inder Anand, Jay N. Cohn

Research output: Contribution to journalArticle

Abstract

Aims: To assess the relationship between body mass index (BMI), mortality and mode of death in chronic heart failure (CHF) patients; to define the shape of the relationship between BMI and mortality. Methods and results: We performed a post-hoc analysis of 5010 patients from the Valsartan Heart Failure Trial. The end-points of the study were all-cause and cardiovascular mortality. Mortality rate was 27.2% in underweight patients (BMI <22 kg/m2), 21.7% in normal weight patients (BMI 22-24.9 kg/m2), 17.9% in overweight patients (BMI 25-29.9 kg/m2) and 16.5% in obese patients (BMI > 30 kg/m2) (p <0.0001). The rates of non-cardiovascular death did not differ among groups. The risk of death due to progressive heart failure was 3.4-fold higher in the underweight than in the obese patients (p <0.0001). Normal weight, overweight and obese patients had lower risk of death as compared with underweight patients (p = 0.019, HR 0.76, 95% CI 0.61-0.96; p = 0.0005, HR 0.68, 95% CI 0.55-0.84; p = 0.003, HR 0.67, 95% CI 0.52-0.88, respectively) independently of symptoms, ventricular function, beta-blocker use, C-reactive protein and brain natriuretic peptide levels. Conclusions: In CHF patients a higher BMI is associated with a better prognosis independently of other clinical variables. The relationship between mortality and BMI is monotonically decreasing.

Original languageEnglish
Pages (from-to)397-402
Number of pages6
JournalEuropean Journal of Heart Failure
Volume9
Issue number4
DOIs
Publication statusPublished - Apr 2007

Keywords

  • Body mass index
  • Heart failure
  • Prognosis

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Body mass index, prognosis and mode of death in chronic heart failure: Results from the Valsartan Heart Failure Trial'. Together they form a unique fingerprint.

  • Cite this

    Cicoira, M., Maggioni, A. P., Latini, R., Barlera, S., Carretta, E., Janosi, A., Soler Soler, J., Anand, I., & Cohn, J. N. (2007). Body mass index, prognosis and mode of death in chronic heart failure: Results from the Valsartan Heart Failure Trial. European Journal of Heart Failure, 9(4), 397-402. https://doi.org/10.1016/j.ejheart.2006.10.016